MedPath

Zero Ischemia Laparoscopic Radio Frequency/Microwave Ablation Assisted Enucleation of Renal Cell Carcinoma With T1 Stage

Not Applicable
Conditions
Kidney Neoplasms
Interventions
Procedure: conventional laparoscopic partial nephrectomy
Procedure: zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)
Registration Number
NCT02734329
Lead Sponsor
RenJi Hospital
Brief Summary

Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for T1a renal cell carcinoma (RCC) in a randomized clinical trial in single center. The investigators want to explore this technique to T1 RCC patients in randomized clinical trial in multiple centers.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
600
Inclusion Criteria
  • patients with sporadic, unilateral, newly diagnosed T1 presumed renal cell carcinoma
  • patients scheduled for laparoscopic nephron sparing surgery
  • patients agreeable to participate in this long-term follow-up study
Exclusion Criteria
  • patients' aged >80 years
  • patients with other renal diseases,(including kidney stone, glomerular nephritis, etc.) which might affect the renal function of the operative kidney
  • patients not able to tolerate the laparoscopic procedure
  • patients with previous renal surgery or history of any inflammatory conditions of the operative kidney
  • patients with the renal tumor involving urinary collecting system

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Conventional groupconventional laparoscopic partial nephrectomyRenal hilum will be accurately isolated and then the artery only will be clamped during surgery.
Zero Ischemia groupzero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)Radiofrequency ablation(RFA) /Microwave ablation(MVA) will be performed for 1 to 4 cycles each depending on tumor size and depth. The tumor then will be laparoscopic enucleation without hilar clamping in most cases.
Primary Outcome Measures
NameTimeMethod
the change in glomerular filtration rate (GFR) of the affected kidneyBaseline and 30 months
changes of estimated GFR (eGFR)Baseline and 30 months
Secondary Outcome Measures
NameTimeMethod
estimated blood lossduring surgery
postoperative complicationspostoperative,up to 30 days
progression-free survival ratethrough study completion, an average of 3 years
rates of positive surgical marginpostoperative,up to 2 weeks after surgery
operative timeDuring surgery
the rate of local recurrencethrough study completion, an average of 3 years
Hospital stay timeThe time from the surgery day to patient discharge, up to 2 weeks

Trial Locations

Locations (1)

Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

🇨🇳

Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath